Oxford BioMedica tanks 24% after earnings alert; brokers take stock

Shares in Oxford BioMedica PLC (LSE:OXB) fell 19% to 479p after the cell and gene therapy manufacturer cut its 2026 guidance, a reaction that reflects the scale of the earnings hit rather than the revenue shortfall alone. Peel Hunt and Stifel, the two brokers to publish on the update, both put the revenue downgrade at about 17% against consensus.